Eisai sets up own sales subsidiary in Vietnam, a fast-growing pharma market

17 September 2020

Aiming to capitalize on a fast-growing Asian market, Japanese drug major Eisai (TYO: 4523) has established a new, wholly-owned, pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam, which will be named Eisai Vietnam Co.

The pharmaceutical market in Vietnam is surpassed in size only by those of Thailand and the Philippines within the Association of Southeast Asian Nations (ASEAN), with the market size reaching $4,199 million in 20191. The compound annual growth rate (CAGR) of the Vietnamese pharmaceutical market from 2014 to 2019 was +10.6%, and it is expected that this market rate will continue to grow in the double digits.

In 1992, Eisai (Thailand) Marketing, a pharmaceutical sales subsidiary of Eisai, started business in Vietnam through a local agency. Eisai opened a representative office in Ho Chi Minh City in 1995, and mainly markets the proton-pump inhibitor Pariet (rabeprazole), muscle relaxant Myonal (eperisone), peripheral neuropathy treatment Methycobal (vitamin B12), and others.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK